Generalized Risk-Adjusted Cost-Effectiveness (GRACE)
GRACE is a method that improves how we measure the value of health treatments by considering how much health benefit they provide, especially for people with more severe or disabling conditions. It goes beyond standard methods by using economic principles to weigh benefits fairly, giving more value to treatments that help those in greater need.
At a glance
Use when
Evaluating treatments for severe or rare diseases; seeking equity-sensitive value assessment; developing value-based pricing models with fairness considerations
Avoid when
Simple cost-effectiveness comparisons are sufficient; data on severity/disability are lacking; regulatory or reimbursement systems require standard QALY/ICER metrics
Inputs
Health outcomes, cost data, severity and disability weights, utility functions reflecting diminishing returns to health
Outputs
Risk-adjusted cost-effectiveness ratios, severity-sensitive value assessments, welfare-optimal pricing or reimbursement recommendations
How it works
GRACE extends traditional cost-effectiveness analysis using welfare economics principles, incorporating diminishing returns to health gains. It generates severity-adjusted and disability-sensitive value weights, offering a theoretically grounded alternative to QALY-based ICER and shared-savings models by optimizing population health utility under equity considerations.
- HTA domains
- Clinical Effectiveness, Costs & Economic Evaluation
- Categories
- Cost-effectiveness Modelling
- Assumptions
- Health gains have diminishing marginal utility; societal preferences favor prioritizing severe and disabling conditions; willingness to pay varies with baseline health status
- Strengths
- Incorporates equity considerations; aligns with welfare economics; sensitive to patient severity and disability; provides principled alternative to ICER and QALY
- Limitations
- Requires robust data on severity and disability; complex to implement; less familiar to policymakers than ICER/QALY; limited real-world adoption
- Also known as
- GRACE
Questions this answers
- › How can we value health gains more fairly across different patient populations?
- › How should severity of illness influence treatment value?
- › How can disability impact be incorporated into cost-effectiveness analysis?
- › What is a welfare-economic alternative to the QALY?
- › How can diminishing returns to health be modeled in HTA?
- › How can value-based pricing reflect equity concerns?
References & sources
Similar by meaning
Beta record. Based on the original catalogue summary; primary-source enrichment pending.